Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - Inotiv, Inc. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and an improvement from a loss of $0.29 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $124.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.41%, compared to year-ago revenues of $119.04 million [2] - Inotiv shares have declined approximately 57.5% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] Group 2 - The earnings outlook for Inotiv is uncertain, with current consensus EPS estimates of -$0.14 on revenues of $124.08 million for the upcoming quarter and -$0.83 on revenues of $494.63 million for the current fiscal year [7] - The estimate revisions trend for Inotiv is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which Inotiv belongs, is currently in the top 26% of Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]